EMA
withdrawal
· 2012-04-30
EMA Application withdrawn: Pioglitazone ratio (pioglitazone) — Ratiopharm GmbH
Summary
The EMA has withdrawn an application for a pioglitazone ratio product by Ratiopharm GmbH, related to Type 2 diabetes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Application withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Ratiopharm GmbH. Decision date: 22/07/2011